Retatrutide, also known as LY3437943, is a peptide-class triple agonist that activates the GIP, GLP-1, and glucagon receptors, but it is not currently FDA-approved for any indication and is not available as an approved prescription product 1, 2, 3
Long-acting agents, on the other hand, provide continuous receptor activation due to structural modifications that slow their absorption, reduce the rate of renal clearance or extend their half-lives [52, 53]
When it comes to prescription drug interventions, however, many weight loss medications have led to their fair share of controversy over the years
Traditional routes for acquiring Semaglutide (Ozempic or Wegovy) involve primary care visits, insurance prior authorizations, and frequent pharmacy stock shortages
When you know why you are drawing a specific volume, you can troubleshoot problems, adjust protocols, and make informed decisions about your research approach
The result is no appetite change that week and confusion about whether the medication works